A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study.

This study suggests caution when prescribing systemic corticosteroids to patients with #COVID19 who show mild-to-moderate pulmonary symptoms because a harmful effect cannot be excluded https://bit.ly/3P4nOjQ.
Competing Interests: Conflict of interest: J. Kocks, M. Kerkhof, A. van de Maat, I. van Geer-Postmus and T. le Rütte were employed by the General Practitioners Research Institute (GPRI) at the time of the study. In the past 3 years (2019–2022), the GPRI conducted investigator- and sponsor-initiated research funded by noncommercial organisations, academic institutes and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis and Teva). H. Kerstjens reports no conflicts of interest for this study; unrelated to this study, his institution has received funding for his studies and payments for his consultancy from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Novartis. R. Gans, J. Scherpenisse and J. Schaart report no conflicts of interest for this study.
(Copyright ©The authors 2022.)